Engage 24: Evaluation of the Safety and Effectiveness of URG101 in Subjects With Interstitial Cystitis/Bladder Pain Syndrome
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02591199|
Recruitment Status : Recruiting
First Posted : October 29, 2015
Last Update Posted : May 4, 2017
|Condition or disease||Intervention/treatment||Phase|
|Interstitial Cystitis Bladder Pain Syndrome||Drug: URG101 Drug: Placebo Drug: Lidocaine Drug: Heparin||Phase 2|
This is a biphasic adaptive design phase 2a, prospective, randomized, double-blind, placebo controlled, multicenter, single-dose, pharmacokinetic study designed to determine the efficacy and safety of the combination product (URG101) with its individual components (Heparin Sodium and Lidocaine Hydrochloride). The study will consist of a run-in phase of 48 subjects and an investigational phase of up to 300 subjects.
Eligible subjects exhibiting moderate to severe symptoms of bladder pain associated with their diagnosis of interstitial cystitis/bladder pain syndrome who have signed informed consent, will be screened and provisionally enrolled for intravesical treatment.
On the day of study drug administration subjects will be randomized (2:1:2:1; URG101:placebo:lidocaine:heparin) and will receive a single administration of one of four intravesical treatments in a blinded fashion, based on random assignment:
- URG101 (buffered lidocaine-heparin)
- Lidocaine Hydrocholoride buffered alone
- Heparin Sodium buffered alone
The study is 24 hours in duration.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||348 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Triple (Participant, Care Provider, Investigator)|
|Official Title:||A Phase 2a, Biphasic Adaptive Design Randomized, Double-Blind, Placebo-Controlled Multi-Center Single Dose Study to Evaluate the Safety and Effectiveness of URG101 Compared With the Individual Components Lidocaine and Heparin in Subjects With Interstitial Cystitis/Bladder Pain Syndrome|
|Study Start Date :||September 2015|
|Estimated Primary Completion Date :||December 2017|
|Estimated Study Completion Date :||December 2017|
A single 15 mL dose of URG101,a mix of buffered Lidocaine (200 mg) and Heparin (50,000 IU), delivered to the bladder via catheter.
Placebo Comparator: Placebo
A single 15 mL dose of placebo delivered to the bladder via catheter.
A single 15 mL dose of buffered Lidocaine (200 mg) delivered to the bladder via catheter.
A single 15 mL dose of buffered Heparin (50,000 IU) delivered to the bladder.
- Change in bladder pain differences from baseline as determined by using the Visual Analog Scale (VAS) [ Time Frame: 24 hours ]The primary objective is to evaluate the change in bladder pain intensity differences from baseline to either 12 hours or 24 hours after administration of URG101 compared with the administration of lidocaine alone, heparin alone, and placebo as determined by using the Visual Analog Scale (VAS).
- Change in urgency from baseline using the VAS [ Time Frame: 24 hours ]Evaluate the change in urgency intensity differences from baseline to 12 or 24 hours after administration of URG101 compared to lidocaine alone, heparin alone, and placebo using the VAS.
- The relationship of plasma lidocaine concentrations at 1 hour after study drug administration to bladder pain and urgency [ Time Frame: 24 hours ]Evaluate the relationship of plasma lidocaine concentrations at 1 hour after study drug administration to bladder pain and urgency at 1 hour, and from baseline to 12 and 24 hours after treatment with URG101 compared to lidocaine alone, heparin alone, and placebo.
- Safety and tolerability of study medication (Adverse events) [ Time Frame: Up to 72 hours ]Adverse events reported after treatment with URG101 compared to lidocaine alone, heparin alone, and placebo.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02591199
|Contact: Kathy Grako, PhD||858-452-7271 ext firstname.lastname@example.org|
|Contact: Nick Osborne, PhDemail@example.com|
|United States, California|
|IC Study, LLC||Recruiting|
|Escondido, California, United States, 92025|
|Contact: Philip C Bosch, MD 760-743-3135|
|University of California San Diego||Recruiting|
|San Diego, California, United States, 92103|
|San Diego, California, United States, 92130|
|Contact: Nancy Giovanetty, CMACRCCRAIII Giovanetty.firstname.lastname@example.org|
|United States, Georgia|
|Cartersville, Georgia, United States, 30120|
|Contact: Tina Cagle, CRMA 770-607-1893 ext 2407 email@example.com|
|United States, Kansas|
|The Urogynecology Center||Recruiting|
|Overland Park, Kansas, United States, 66209|
|Contact: Margaret R Sanford, APRN HQuilty@urogyncenter.com|
|United States, New York|
|The Arthur Smith Institue for Urology- North Shore Long Island Jewish Health System||Recruiting|
|Lake Success, New York, United States, 11042|
|Contact: Monica Johnson, RN 516-734-8515 firstname.lastname@example.org|
|United States, North Carolina|
|Wake Forest University Health Sciences||Recruiting|
|Winston-Salem, North Carolina, United States, 27103|
|Contact: Janet Shuping email@example.com|
|United States, Ohio|
|MetroHealth System, Center for Advanced Gynecology||Recruiting|
|Cleveland, Ohio, United States, 44109|
|Contact: Adriana E Perez firstname.lastname@example.org|
|Contact: Rozina Aamir email@example.com|
|United States, South Carolina|
|Medical University of South Carolina||Not yet recruiting|
|Charleston, South Carolina, United States, 29425|
|Contact: Jessica Jenkins firstname.lastname@example.org|
|United States, South Dakota|
|Sioux Falls, South Dakota, United States, 57105|
|Contact: Jessica Wittrock email@example.com|
|United States, Virginia|
|Urology of Virginia, PLLC||Recruiting|
|Virginia Beach, Virginia, United States, 23462|
|Contact: Michele Schindler firstname.lastname@example.org|
|Study Chair:||C. Lowell Parsons, MD||Urigen|